To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
CancerNetwork Karmanos Cancer Institute experts in multiple myeloma and chronic myeloid leukemia (CML) took part in a face-off against Cleveland Clinic. Andrew Kin, M.D. , hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant , Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams (MDTs), was the team captain for Karmanos. He was joined by Craig Cole, M.D. , hematologist, member of the Hematology Oncology and Multiple Myeloma and Amyloidos...
Patient Power Jay Yang, M.D. , hematologist, medical oncologist and leader of the Hematology Oncology Multidisciplinary Team , explains the types of treatments available to myelofibrosis (MF) patients depending on their risk. Genetic mutations, chronic inflammation, certain blood disorders or having been exposed to certain industrial chemicals can influence a person’s risk of developing MF. Read the article here .
Patient Power Jay Yang, M.D. , hematologist, medical oncologist and leader of the Hematology Oncology Multidisciplinary Team , discusses the treatment options for patients and the prognosis of living with essential thrombocythemia (ET). Read the article here .